Evidence map›Paper›PMID 39841354›Full record

SynthesisEndocrine2025

Prevalence of metabolic syndrome among pregnant women: a systematic review and meta-analysis.

A Mohebi, M M Pathirana, A Khoja, M R Wittwer, K Lowe, D Fisher, S Kharwadkar, C Gomes, T Gamage, E Toyer and 3 more

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Observational
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

A MohebiAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
M M PathiranaAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
A KhojaAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
M R WittwerDepartment of Cardiology, Lyell McEwin Hospital, Elizabeth Vale, Adelaide, SA, Australia.
K LoweDepartment of Cardiology, Lyell McEwin Hospital, Elizabeth Vale, Adelaide, SA, Australia.
D FisherAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
S KharwadkarAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
C GomesAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
T GamageAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
E ToyerAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
S YoungAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
M A ArstallAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia.
P H AndraweeraAdelaide Medical School, The University of Adelaide, Adelaide, SA, Australia. prabha.andraweera@adelaide.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMetabolic syndrome (MetS) is a cluster of risk factors that increase the risk of cardiometabolic diseases. The prevalence of MetS and individual components across pregnancy has not been reviewed in the literature. This research was conducted to identify the prevalence of MetS and its components among pregnant women.

methodsThe PubMed, EMBASE, CINAHL, Web of Science and Scopus databases were searched. The review protocol is registered in PROSPERO (CRD42023460729). Quality assessment was performed using the JBI critical appraisal checklist. The study selection, data extraction and data analyses were performed in accordance with the MOOSE guidelines.

resultsThe prevalence of MetS among pregnant women was 16.3%, (n = 3946). The prevalences for individual MetS components were: low HDL, 12.3% (n = 1108); high fasting glucose, 16.2% (n = 2333); high triglycerides, 48.5% (n = 2880); obesity, 42.7% (n = 5162) and high blood pressure 37.7% (n = 828). According to the definitions used to diagnose MetS, the prevalences were 18.2% according to the World Health Organization, 15.0% according to the International Diabetes Federation and 17.2% according to the National Cholesterol Education Program Adult Treatment Panel III. When stratified by gestational age at assessment, the prevalence of MetS was 9.9% before 16 weeks' and 24.1% after 20 weeks' of gestation.

conclusionThis review demonstrates that MetS is detected in approximately one-fifth of pregnant women. Screening for MetS and its components during pregnancy may help identify young women at risk for future cardiovascular disease.

Indexed as

Metabolic SyndromePregnancy ComplicationsFemaleHumansPregnancyPrevalenceCardiovascularMeta analysisMetabolic syndromeObesityPregnancyPrevalence

Identifiers

PMID39841354
PMCPMC12069128

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.